Senesco Technologies, Inc. – Dr. Harlan Waksal: “The Powerful Possibilities Behind the Senesco/Fabrus Combination”

Follow this company

Companies Mentioned

06/10/2014 [ACCESSWIRE]

New York, NY / June 10, 2014 / Senesco Technologies, Inc. (OTCQB: SNTI) today published a new blog post on The Chairman’s Blog, written by the Company’s Chairman of the Board of Directors, Dr. Harlan Waksal. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his new blog post, Dr. Waksal reflects on the opportunities presented by Senesco’s decision to merge with Fabrus, Inc. Commenting on how they will work together, Dr. Waksal writes, "...the two companies' complementarity goes much further than simply one pipeline candidate." Read the full blog post from Dr. Waksal on (  

About Senesco Technologies

Senesco Technologies is a clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to eliminate cancer cells and protect healthy cells from premature death. The Company is currently in a Phase 1b/2a trial with a product candidate that is designed to treat B-cell cancers, which include multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s B-cell lymphomas. The technology was developed over the last 15 years through the discovery that the genetic pathway for cell growth control is common to both plants and humans. For more information, please visit or connect with us on Facebook, Twitter, LinkedIn and Google+.

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. 

SOURCE: The Chairmans Blog  


Leave a comment...

Your Name